New joint Position Statement published on safe treatment of hyperprolactinaemia
01 Mar 2019
The paper, “Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology” was published today in both Clinical Endocrinology and Echo Research and Practice.
This joint statement, written collaboratively by the key Societies with an interest in this condition, is important reading for any general medical professionals, as well as those in the cardiovascular and endocrine fields, that are involved in managing patients with hyperprolactinaemia, to ensure they are treated effectively and safely.
Clinical Endocrinology is the Society’s official clinical journal and is available free online to members. Sign up for free email alerts on the Clinical Endocrinology homepage and download the free app to have access to all this content at your fingertips.
Echo Research and Practice is the official journal of the British Society of Echocardiography and is published by Bioscientifica, the Society for Endocrinology’s fully owned subsidiary that redistributes all its profits back to the Society.